{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:25:42Z","timestamp":1773865542446,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Vice-Chancellor of Research of Mashhad University of Medical Sciences","award":["930125"],"award-info":[{"award-number":["930125"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The current study aimed to evaluate growth and neurodevelopmental status in patients with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This historical cohort study was conducted on neonates with ROP who were treated with IVB and age and birth weight-matched controls who did not need IVB. Apgar score less than five, history of blood transfusion and history of infectious diseases were among exclusion criteria. Indirect ophthalmoscopic examinations were performed till complete retinal vascularization. Growth and neurodevelopmental status were evaluated by Age and Stages Questionnaire (ASQ) at the ages of 6, 12, and 18\u00a0months. Developmental milestones were assessed in five areas (gross motor, fine motor, personal-social status, problem-solving, and relationship) and overall issues.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 34 cases and 36 controls were included in the present study. Birth weight and corrected gestational age were not statistically different between the groups. In a follow-up period of 18\u00a0months, bevacizumab was effective as a primary treatment in the treatment of severe cases of ROP. There was no significant difference between the two groups regarding the five areas and overall issues in follow-up intervals (P\u2009&gt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The obtained results did not show any growth and neurodevelopmental differences between treatment-na\u00efve infants and those receiving IVB for the treatment of ROP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40942-021-00340-6","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T10:02:55Z","timestamp":1637056975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case\u2013control study"],"prefix":"10.1186","volume":"7","author":[{"given":"Majid","family":"Abrishami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Boskabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojtaba","family":"Abrishami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Shekarchian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Khadem-Rezaiyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3544-0105","authenticated-orcid":false,"given":"Nasser","family":"Shoeibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"issue":"1","key":"340_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S1091-8531(99)70091-1","volume":"3","author":"PG Steinkuller","year":"1999","unstructured":"Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK. Childhood blindness. J Am Assoc Pediatr Ophthalmol Strabismus. 1999;3(1):26\u201332.","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"issue":"3","key":"340_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.5812\/ircmj.4513","volume":"15","author":"M Abrishami","year":"2013","unstructured":"Abrishami M, Maemori G-A, Boskabadi H, Yaeghobi Z, Mafi-Nejad S, Abrishami M. Incidence and risk factors of retinopathy of prematurity in mashhad, northeast iran. Iran Red Crescent Med J. 2013;15(3):229.","journal-title":"Iran Red Crescent Med J"},{"issue":"7","key":"340_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"340_CR4","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.18240\/ijo.2019.07.15","volume":"12","author":"Q-Y Meng","year":"2019","unstructured":"Meng Q-Y, Cheng Y, Zhao M-W, Liang J-H. The process of retinal vascularization in retinopathy of prematurity after ranibizumab treatment in China. Int J Ophthalmol. 2019;12(7):1146.","journal-title":"Int J Ophthalmol"},{"issue":"4","key":"340_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2165\/00129785-200303040-00004","volume":"3","author":"H Mechoulam","year":"2003","unstructured":"Mechoulam H, Pierce EA. Retinopathy of prematurity: molecular pathology and therapeutic strategies. Am J Pharmacogenomics. 2003;3(4):261\u201377.","journal-title":"Am J Pharmacogenomics"},{"issue":"6","key":"340_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ophtha.2007.08.050","volume":"115","author":"K Sonmez","year":"2008","unstructured":"Sonmez K, Drenser KA, Capone A Jr, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology. 2008;115(6):1065-70 e1.","journal-title":"Ophthalmology"},{"issue":"9","key":"340_CR7","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.ophtha.2008.12.023","volume":"116","author":"T Sato","year":"2009","unstructured":"Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology. 2009;116(9):1599\u2013603.","journal-title":"Ophthalmology"},{"issue":"6","key":"340_CR8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28(6):831\u20138.","journal-title":"Retina"},{"issue":"1","key":"340_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","volume":"118","author":"WC Wu","year":"2011","unstructured":"Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Ophthalmology. 2011;118(1):176\u201383.","journal-title":"Ophthalmology"},{"issue":"2","key":"340_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153(2):327-33 e1.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"340_CR11","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1167\/iovs.09-4140","volume":"51","author":"T Miyake","year":"2010","unstructured":"Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 2010;51(3):1606\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"340_CR12","volume-title":"Ages & stages questionnaires\u00ae:social-emotional, second edition (ASQ\u00ae:SE-2). A parent-completed child monitoring system for social-emotional behaviors","author":"J Squires","year":"2015","unstructured":"Squires J, Bricker D, Twombly E. Ages & stages questionnaires\u00ae:social-emotional, second edition (ASQ\u00ae:SE-2). A parent-completed child monitoring system for social-emotional behaviors. Baltimore, London, Sydney: Brookes Publishing Co; 2015."},{"issue":"2","key":"340_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1046\/j.1440-1754.2001.00604.x","volume":"37","author":"CY Skellern","year":"2001","unstructured":"Skellern CY, Rogers Y, O\u2019Callaghan MJ. A parent-completed developmental questionnaire: follow up of ex-premature infants. J Paediatr Child Health. 2001;37(2):125\u20139.","journal-title":"J Paediatr Child Health"},{"issue":"11","key":"340_CR14","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1080\/08035250600684438","volume":"95","author":"AM Plomgaard","year":"2006","unstructured":"Plomgaard AM, Hansen BM, Greisen G. Measuring developmental deficit in children born at gestational age less than 26 weeks using a parent-completed developmental questionnaire. Acta Paediatr. 2006;95(11):1488\u201394.","journal-title":"Acta Paediatr"},{"issue":"5","key":"340_CR15","first-page":"522","volume":"42","author":"R Vameghi","year":"2013","unstructured":"Vameghi R, Sajedi F, Kraskian Mojembari A, Habiollahi A, Lornezhad HR, Delavar B. Cross-cultural adaptation, validation and standardization of ages and stages questionnaire (ASQ) in Iranian children. Iran J Public Health. 2013;42(5):522\u20138.","journal-title":"Iran J Public Health"},{"issue":"7","key":"340_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group B-RC. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u201315.","journal-title":"N Engl J Med"},{"issue":"6","key":"340_CR17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/APO.0000000000000039","volume":"3","author":"D Hapsari","year":"2014","unstructured":"Hapsari D, Sitorus RS. Intravitreal bevacizumab in retinopathy of prematurity: inject or not? Asia Pac J Ophthalmol. 2014;3(6):368\u201378.","journal-title":"Asia Pac J Ophthalmol"},{"issue":"2","key":"340_CR18","doi-asserted-by":"publisher","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","volume":"98","author":"BA Darlow","year":"2013","unstructured":"Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. 2013;98(2):F170\u20134.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"2","key":"340_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","volume":"33","author":"MA Martinez-Castellanos","year":"2013","unstructured":"Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, Kon-Jara VA, Garcia-Aguirre G, Guerrero-Naranjo JL, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina. 2013;33(2):329\u201338.","journal-title":"Retina"},{"issue":"2","key":"340_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clp.2013.02.005","volume":"40","author":"DK Wallace","year":"2013","unstructured":"Wallace DK, Wu KY. Current and future trends in treatment of severe retinopathy of prematurity. Clin Perinatol. 2013;40(2):297\u2013310.","journal-title":"Clin Perinatol"},{"issue":"10","key":"340_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223972","volume":"14","author":"Y-S Chang","year":"2019","unstructured":"Chang Y-S, Chen Y-T, Lai T-T, Chou H-C, Chen C-Y, Hsieh W-S, et al. Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment. PloS ONE. 2019;14(10): e0223972.","journal-title":"PloS ONE"},{"key":"340_CR22","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard M-N, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016. https:\/\/doi.org\/10.1542\/peds.2015-3218.","journal-title":"Pediatrics"},{"issue":"3","key":"340_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230678","volume":"15","author":"M Arima","year":"2020","unstructured":"Arima M, Akiyama M, Fujiwara K, Mori Y, Inoue H, Seki E, et al. Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity. PloS ONE. 2020;15(3): e0230678.","journal-title":"PloS ONE"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-021-00340-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-021-00340-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-021-00340-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T10:12:16Z","timestamp":1637057536000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-021-00340-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["340"],"URL":"https:\/\/doi.org\/10.1186\/s40942-021-00340-6","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"assertion":[{"value":"10 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol adhered to the tenets of the Declaration of Helsinki. All participants provided written informed consent before enrollment and the ethical aspects of the study were approved by the Regional Committee on Medical Ethics at Mashhad University of Medical Sciences, Mashhad, Iran (IR.MUMS.REC.1393.78).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Because the cases and controls are anonymous and were not depicted in the report, consent for publication is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}